Pharmacopsychiatry
January 19, 2022
Hitoshi Sakurai, Kengo Yonezawa, Hideaki Tani et al.
35 citations
Nine antidepressant compounds with mechanisms beyond the monoaminergic hypothesis have shown positive results in phase II or III trials. AXS-05 (dextromethorphan and bupropion) and ansofaxine hydrochloride outperformed placebo in phase III trials for major depressive disorder or treatment-resistant depression. MIJ821, nitrous oxide, psilocybin, ayahuasca, botulinum toxin A facial injection, prasterone, and casopitant each showed at least one positive phase II result. Ayahuasca produced a greater response rate than placebo at one week, suggesting rapid antidepressant effects. These novel compounds may expand treatment options if preliminary findings are confirmed.
Pharmacopsychiatry
July 30, 2023
Kengo Yonezawa, H. Uchida, T. Yatomi et al.
8 citations
Later age of depression onset is linked to a better treatment response three days after intravenous ketamine in adults with treatment-resistant depression. In a placebo-controlled, double-blind, randomized trial of 31 patients (13 women; average age 48.4 years), logistic regression showed that older age at onset positively correlated with response after three days. No associations were found between response and age, sex, baseline depression severity, or dissociative symptoms. Multiple regression found no factors significantly correlated with change in depression scores. The authors suggest that earlier onset may impair glutamatergic signaling and neuroplasticity, reducing ketamine's effectiveness.
PCN reports : psychiatry and clinical neurosciences
September 1, 2023
Chisato Tanaka, Kenta Wakaizumi, Akira Ninomiya et al.
3 citations
Among graduates of mindfulness-based interventions (MBIs) during the COVID-19 pandemic, those who continued regular mindfulness practice reported lower depression and higher resilience, overall health, and mental health compared to those who did not practice. The degree of perceived stress from the pandemic did not differ statistically between the groups. The effect of mindfulness practice on reducing depression was fully mediated by resilience. The findings suggest that maintaining mindfulness practice after an MBI builds resilience, which helps buffer against new stressors and may prevent depression.